Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer

NCT00074867 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

29

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Neoplasms
Peritoneal Neoplasms
Fallopian Tube Neoplasms

Interventions

DRUG: CP-547,632

Sponsor

Pfizer